ConductScience.org, home

Paper2420009

Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.

Souza LM and 14 others. Science, 1986. Cited by 1,335 papers, by iCite.

Cite this record

ConductScience Library. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Papers, record 2420009. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2420009

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.
PubMed
Journal
Science
PubMed
Year
1986
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
1,335
iCite
Relative citation ratio, by iCite
35.7
iCite
Revised in PubMed
2024-01-09
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Souza LML M
2Boone TCT C
3Gabrilove JJ
4Lai PHP H
5Zsebo KMK M
6Murdock DCD C
7Chazin VRV R
8Bruszewski JJ
9Lu HH
10Chen KKK K
11Barendt JJ
12Platzer EE
13Moore MASM A S
14Mertelsmann RR
15Welte KK

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colony-Stimulating FactorsMajor topic
GranulocytesMajor topic
LeukemiaMajor topic
Recombinant ProteinsMajor topic
Animals
Cell Differentiation
Cell Line
Colony-Forming Units Assay
DNA
Escherichia coli
Genes
Granulocyte Colony-Stimulating Factor
Humans
Leukemia, Myeloid
Mice
Plasmids

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA00966NCI NIH HHSUnited StatesK08CA000966PubMed and NIHNIH RePORTER
CA20194NCI NIH HHSUnited StatesP01CA020194PubMed and NIHNIH RePORTER
CA32516NCI NIH HHSUnited StatesR01CA032516PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01933971
Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®
Background

Source ClinicalTrials.gov

Download CSV of trials

Cited by221

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,335 citations.

PMIDTitleJournalYearIn PapersSource
42178347Evaluation of bone mineral density in patients with severe congenital neutropenia: experience of six centers in Turkey.Sci Rep2026https://conductscience.org/library/papers/42178347PubMed
41981080Blood cell-derived transplants at 40.Bone Marrow Transplant2026https://conductscience.org/library/papers/41981080PubMed
39638788Neutrophil diversity and function in health and disease.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39638788PubMed
39009900Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer.Int J Clin Oncol2024https://conductscience.org/library/papers/39009900PubMed
38814416Progress in the treatment of Osteoarthritis with avocado-soybean unsaponifiable.Inflammopharmacology2024https://conductscience.org/library/papers/38814416PubMed
38732026Balancing Benefits and Risks: A Literature Review on Hypersensitivity Reactions to Human G-CSF (Granulocyte Colony-Stimulating Factor).Int J Mol Sci2024https://conductscience.org/library/papers/38732026PubMed
38672505Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey.Biomolecules2024https://conductscience.org/library/papers/38672505PubMed
38556793CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia.Mol Ther2024https://conductscience.org/library/papers/38556793PubMed
37638739Improving the Therapeutic Potential of G-CSF through Compact Circular PEGylation Based on Orthogonal Conjugations.Biomacromolecules2023https://conductscience.org/library/papers/37638739PubMed
36951655Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).Cancer Med2023https://conductscience.org/library/papers/36951655PubMed
36313476Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response.Int J Pept Res Ther2022https://conductscience.org/library/papers/36313476PubMed
35739328Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF).Support Care Cancer2022https://conductscience.org/library/papers/35739328PubMed
35618709A topological refactoring design strategy yields highly stable granulopoietic proteins.Nat Commun2022https://conductscience.org/library/papers/35618709PubMed
35324270Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.JCO Glob Oncol2022https://conductscience.org/library/papers/35324270PubMed
34631440Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors.World J Clin Oncol2021https://conductscience.org/library/papers/34631440PubMed
33923357The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.Int J Mol Sci2021https://conductscience.org/library/papers/33923357PubMed
33789928Viral Respiratory Pathogens and Lung Injury.Clin Microbiol Rev2021https://conductscience.org/library/papers/33789928PubMed
33787864Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study.Blood Adv2021https://conductscience.org/library/papers/33787864PubMed
33677228G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation.Cytokine2021https://conductscience.org/library/papers/33677228PubMed
33598399Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience.Leuk Res Rep2021https://conductscience.org/library/papers/33598399PubMed

See all 221 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CSF31440Swiss-Prot's referenceshttps://conductscience.org/library/genes/1440

Source NCBI Gene

Download CSV of genes

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
GENBANKM13008

Source GENBANK

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2420009

GET https://conductscience.org/api/papers/v1/2420009/cited_by?page=2